Panacea Biotec has announced that no shares were dematerialised during April 2026. The company confirmed this in its regulatory filing, citing compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
As of 30 April 2026, the total number of shares dematerialised remained unchanged from the previous month, with 5,36,44,500 shares under the National Securities Depository Limited (NSDL) and 74,60,026 shares under the Central Depository Services Limited (CDSL), bringing the total to 6,11,04,526 shares.
The company also attached a certificate from its Registrar and Share Transfer Agent, Skyline Financial Services Pvt. Ltd., confirming the dematerialised shares status as of the end of April 2026.
This update was provided to ensure transparency and compliance with the regulatory requirements for listed securities.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).